Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®

Exclusion Criteria

• •Previous treatment by immunotherapy with grass allergen extracts.
• •A clinical history of symptomatic perennial allergic rhinitis or asthma.
• •Patients with contraindications for immunotherapy as established by the IT subcommittee of the EAACI or in the Summary of Products Characteristics of GRAZAX®.
• •Positive pregnancy test (in fertile females).
• •Being immediate family of the investigator or trial staff.
• •A mental condition rendering the subject unable to understand the nature, scope and possible consequences of the trial, and/or evidence of an uncooperative attitude.
• •Unlikely to be able to complete the trial, for any reason, or likely to move, or travel for extended periods of time during the trial period.
• •Use of an investigational drug within 30 days or 5 half-lives, whichever is longest, prior to screening.